$EDIT
Editas Medicine, Inc.

2020 Q4 Form 10-Q Financial Statement

#000155837020013022 Filed on November 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $11.42M $62.84M $3.848M
YoY Change -7.04% 1533.08% -73.5%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $15.79M $19.94M $15.73M
YoY Change -6.68% 26.76% 18.0%
% of Gross Profit
Research & Development $61.50M $33.92M $22.70M
YoY Change 76.77% 49.4% 30.15%
% of Gross Profit
Depreciation & Amortization $1.180M $1.110M $730.0K
YoY Change 51.28% 52.05% -12.05%
% of Gross Profit
Operating Expenses $77.29M $53.85M $38.44M
YoY Change 49.48% 40.11% 24.89%
Operating Profit $8.989M -$34.59M
YoY Change -125.99% 112.74%
Interest Expense $230.0K $230.0K $1.680M
YoY Change -86.06% -86.31% 64.71%
% of Operating Profit 2.56%
Other Income/Expense, Net $3.375M -$1.170M $1.647M
YoY Change 104.17% -171.04% 61.47%
Pretax Income -$62.50M $7.820M -$32.94M
YoY Change 65.48% -123.74% 116.14%
Income Tax
% Of Pretax Income
Net Earnings -$62.50M $7.819M -$32.94M
YoY Change 65.47% -123.74% 116.18%
Net Earnings / Revenue -547.32% 12.44% -856.06%
Basic Earnings Per Share -$1.00 $0.13 -$0.66
Diluted Earnings Per Share -$1.00 $0.12 -$0.66
COMMON SHARES
Basic Shares Outstanding 62.33M 62.14M 49.82M
Diluted Shares Outstanding 62.70M 49.82M

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $402.1M $495.3M $441.1M
YoY Change -42.47% 12.3% 30.68%
Cash & Equivalents $139.7M $279.6M $104.8M
Short-Term Investments $262.4M $215.7M $336.3M
Other Short-Term Assets $10.90M $10.50M $6.300M
YoY Change 73.02% 66.67% 26.0%
Inventory
Prepaid Expenses
Receivables $6.000M $1.100M $300.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $419.1M $506.8M $339.2M
YoY Change -9.65% 49.41% -0.99%
LONG-TERM ASSETS
Property, Plant & Equipment $14.02M $14.07M $10.08M
YoY Change 28.78% 39.64% -74.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $109.7M $46.00M
YoY Change
Other Assets $4.703M $3.877M $5.392M
YoY Change -12.79% -28.1% -0.15%
Total Long-Term Assets $153.5M $90.33M $33.15M
YoY Change 240.83% 172.51% -26.34%
TOTAL ASSETS
Total Short-Term Assets $419.1M $506.8M $339.2M
Total Long-Term Assets $153.5M $90.33M $33.15M
Total Assets $572.6M $597.2M $372.4M
YoY Change 12.52% 60.37% -3.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.408M $5.158M $6.624M
YoY Change 9.67% -22.13% 32.48%
Accrued Expenses $24.05M $20.31M $8.138M
YoY Change 8.71% 149.53% -27.98%
Deferred Revenue $20.94M $19.87M $46.02M
YoY Change -10.93% -56.81%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $58.21M $54.82M $66.79M
YoY Change -2.93% -17.92% 155.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $27.50M $101.2M $1.000K
YoY Change 2749900.0% 10119900.0% -100.0%
Total Long-Term Liabilities $27.50M $101.2M $1.000K
YoY Change 2749900.0% 10119900.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $58.21M $54.82M $66.79M
Total Long-Term Liabilities $27.50M $101.2M $1.000K
Total Liabilities $179.0M $156.0M $162.4M
YoY Change -27.36% -3.92% -0.51%
SHAREHOLDERS EQUITY
Retained Earnings -$665.2M -$602.7M -$511.5M
YoY Change 21.12% 17.83%
Common Stock $1.059B $1.044B $721.4M
YoY Change 30.47% 44.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $393.6M $441.2M $210.0M
YoY Change
Total Liabilities & Shareholders Equity $572.6M $597.2M $372.4M
YoY Change 12.52% 60.37% -3.93%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$62.50M $7.819M -$32.94M
YoY Change 65.47% -123.74% 116.18%
Depreciation, Depletion And Amortization $1.180M $1.110M $730.0K
YoY Change 51.28% 52.05% -12.05%
Cash From Operating Activities -$40.10M -$54.80M -$26.88M
YoY Change -197.76% 103.87% 242.86%
INVESTING ACTIVITIES
Capital Expenditures -$1.370M -$1.800M -$2.250M
YoY Change -18.93% -20.0% 139.36%
Acquisitions
YoY Change
Other Investing Activities -$107.5M -$150.5M -$120.1M
YoY Change -1230.6% 25.33% 846.85%
Cash From Investing Activities -$108.9M -$152.3M -$122.3M
YoY Change -1492.46% 24.5% 798.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.100M 820.0K 43.36M
YoY Change -89.24% -98.11% 3396.77%
NET CHANGE
Cash From Operating Activities -40.10M -54.80M -26.88M
Cash From Investing Activities -108.9M -152.3M -122.3M
Cash From Financing Activities 9.100M 820.0K 43.36M
Net Change In Cash -139.9M -206.3M -105.8M
YoY Change -204.87% 94.89% 423.39%
FREE CASH FLOW
Cash From Operating Activities -$40.10M -$54.80M -$26.88M
Capital Expenditures -$1.370M -$1.800M -$2.250M
Free Cash Flow -$38.73M -$53.00M -$24.63M
YoY Change -190.68% 115.18% 256.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
us-gaap:ServiceMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
us-gaap:ServiceMember
CY2020Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
us-gaap:ServiceMember
dei Entity Central Index Key
EntityCentralIndexKey
0001650664
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
us-gaap:ServiceMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37687
dei Entity Registrant Name
EntityRegistrantName
EDITAS MEDICINE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4097528
dei Entity Address Address Line1
EntityAddressAddressLine1
11 Hurley Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02141
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
401-9000
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
EDIT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
62334218
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
279576000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
238183000
CY2020Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
215729000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
218957000
CY2020Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
1055000
CY2019Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
418000
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10467000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6286000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
506827000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
463844000
CY2020Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
45986000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14069000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10887000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26398000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28761000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3877000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5393000
CY2020Q3 us-gaap Assets
Assets
597157000
CY2019Q4 us-gaap Assets
Assets
508885000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5158000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5843000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20307000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22120000
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
19874000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
23514000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6342000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5804000
CY2020Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3135000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2682000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
54816000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
59963000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20368000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23277000
CY2020Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
80821000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
163207000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1000
CY2020Q3 us-gaap Liabilities
Liabilities
156005000
CY2019Q4 us-gaap Liabilities
Liabilities
246448000
CY2020Q3 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0.0001
CY2019Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0.0001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
195000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
195000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62331700
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54533798
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62187700
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54355798
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
6000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1043892000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
811546000
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-48000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
107000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-602698000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-549221000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
441152000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
262437000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
597157000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
508885000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
62841000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3848000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
79313000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8247000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33916000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22702000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
96492000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62109000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19936000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15734000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
51789000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
47638000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
53852000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
38436000
us-gaap Operating Expenses
OperatingExpenses
148281000
us-gaap Operating Expenses
OperatingExpenses
109747000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
8989000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-34588000
us-gaap Operating Income Loss
OperatingIncomeLoss
-68968000
us-gaap Operating Income Loss
OperatingIncomeLoss
-101500000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1396000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-33000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13114000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-144000
CY2020Q3 us-gaap Investment Income Net
InvestmentIncomeNet
226000
CY2019Q3 us-gaap Investment Income Net
InvestmentIncomeNet
1680000
us-gaap Investment Income Net
InvestmentIncomeNet
2377000
us-gaap Investment Income Net
InvestmentIncomeNet
5668000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1170000
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1647000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
15491000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5524000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
7819000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-32941000
us-gaap Net Income Loss
NetIncomeLoss
-53477000
us-gaap Net Income Loss
NetIncomeLoss
-95976000
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.95
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.12
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.95
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62144118
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49820455
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57377581
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49246684
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62697173
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49820455
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57377581
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49246684
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
7819000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-32941000
us-gaap Net Income Loss
NetIncomeLoss
-53477000
us-gaap Net Income Loss
NetIncomeLoss
-95976000
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-231000
CY2019Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-6000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-155000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
68000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
7588000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32947000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53632000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-95908000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
262437000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3047000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6220000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
587000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5845000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-231000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
7819000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
441152000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
236162000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1533000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-37724000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
234567000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6839000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
203682000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5417000
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
350000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-511000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-23572000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
426772000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
947000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7855000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
58000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-29249000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
217162000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2894000
CY2019Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
410000
CY2019Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
283000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6083000
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
16000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-33786000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
193062000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1329000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6559000
CY2019Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
100000
CY2019Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
41987000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-6000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-32941000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
209990000
us-gaap Profit Loss
ProfitLoss
-53477000
us-gaap Profit Loss
ProfitLoss
-95976000
us-gaap Share Based Compensation
ShareBasedCompensation
17483000
us-gaap Share Based Compensation
ShareBasedCompensation
20907000
us-gaap Depreciation
Depreciation
2776000
us-gaap Depreciation
Depreciation
2048000
us-gaap Equity Securities Fv Ni Unrealized Gain
EquitySecuritiesFvNiUnrealizedGain
13109000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
285000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2427000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
637000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
281000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4181000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-263000
edit Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-2363000
edit Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-1780000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-106000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
14000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-447000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1005000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
300363000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
305126000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2391000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4491000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-86026000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2928000
edit Increase Decrease In Right Of Use Liability
IncreaseDecreaseInRightOfUseLiability
-2371000
edit Increase Decrease In Right Of Use Liability
IncreaseDecreaseInRightOfUseLiability
-2107000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
453000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
528000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-139743000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-81693000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5786000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4476000
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
21000
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
36000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
274500000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
314000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-31628000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4434000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
203839000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
41216000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10833000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5756000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
350000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
283000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
215022000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
47255000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
43651000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-30004000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
239802000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
136395000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
283453000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
106391000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
910000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
772000
edit Receivable Of Proceeds From Offering Of Common Stock
ReceivableOfProceedsFromOfferingOfCommonStock
756000
us-gaap Operating Lease Payments
OperatingLeasePayments
7757000
us-gaap Operating Lease Payments
OperatingLeasePayments
4604000
edit Non Cash Transactions Offering Cost Included In Accounts Payable And Accrued Expenses
NonCashTransactionsOfferingCostIncludedInAccountsPayableAndAccruedExpenses
158000
edit Non Cash Transactions Offering Cost Included In Accounts Payable And Accrued Expenses
NonCashTransactionsOfferingCostIncludedInAccountsPayableAndAccruedExpenses
15000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
19461000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">1. Nature of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Editas Medicine, Inc. (the “Company”) is a leading, clinical stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The Company was incorporated in the state of Delaware in September 2013. Its principal offices are in Cambridge, Massachusetts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and raising capital. The Company has primarily financed its operations through various equity financings, payments received under a research collaboration with Juno Therapeutics, Inc., a wholly-owned subsidiary of the Bristol-Myers Squibb Company (“Juno Therapeutics”), and payments received under a strategic alliance with Allergan Pharmaceuticals International Limited <span style="background-color:#ffffff;color:#212529;">(which was acquired by AbbVie, Inc. in May 2020 and is referred to together with its affiliates as “Allergan”). In August 2020, the collaboration with Allergan was terminated.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and ability to transition from pilot-scale manufacturing to large-scale production of products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;">Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In May 2020, the Company entered into a sales agreement with Cowen and Company, LLC (“Cowen”), under which the Company from time to time can issue and sell shares of its common stock through Cowen in at-the-market offerings for aggregate gross sale proceeds of up to $150.0 million ( the “ATM Facility”). As of September 30, 2020, the Company has not sold any shares of its common stock under the ATM Facility. In June 2020, the Company completed a public offering whereby the Company sold 6,900,000 shares of its common stock, inclusive of 900,000 shares of common stock sold by the Company pursuant to the full exercise of an option granted to the underwriters in connection with the offering and received net proceeds of approximately $203.7 million. As of September 30, 2020, the Company has raised an aggregate of $648.7 million in net proceeds through the sale of shares of its common stock in public offerings and at-the-market offerings. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;">The Company has incurred annual net operating losses in every year since its inception. The Company expects that its existing cash, cash equivalents and marketable securities</span> <span style="font-size:10pt;">at September 30, 2020 and anticipated interest income will enable it to fund its operating expenses and capital expenditure requirements </span><span style="font-size:10pt;">into 2023</span><span style="font-size:10pt;">. The Company had an accumulated deficit of $602.7 million at September 30, 2020, and will require substantial additional capital to fund its operations. The Company has never generated any product revenue. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate product revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition.</span></p>
CY2020Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
6900000
CY2020Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
203700000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-602700000
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
528231000
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
13129000
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
69000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
541291000
CY2019Q4 edit Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
460700000
CY2019 edit Marketable Securities Unrealized Gain
MarketableSecuritiesUnrealizedGain
107000
CY2019Q4 us-gaap Marketable Securities
MarketableSecurities
460807000
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2020Q3 edit Marketable Securities Noncurrent Number Of Securities
MarketableSecuritiesNoncurrentNumberOfSecurities
21
CY2020Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
46000000.0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10887000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6634000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4971000
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5037000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
674000
CY2020Q3 edit Process And Platform Development Costs Current
ProcessAndPlatformDevelopmentCostsCurrent
5019000
CY2019Q4 edit Process And Platform Development Costs Current
ProcessAndPlatformDevelopmentCostsCurrent
735000
CY2020Q3 edit Accrued Intellectual Property Fees
AccruedIntellectualPropertyFees
2653000
CY2019Q4 edit Accrued Intellectual Property Fees
AccruedIntellectualPropertyFees
3725000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
964000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
599000
CY2019Q4 edit Sublicensing Expenses
SublicensingExpenses
11416000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20307000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22120000
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
23988000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18091000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9919000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7204000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14069000
CY2019Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
418000
edit Accounts Receivable Additions
AccountsReceivableAdditions
946000
edit Accounts Receivable Deductions
AccountsReceivableDeductions
309000
CY2020Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
1055000
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
186721000
edit Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
508000
edit Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
86534000
CY2020Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
100695000
CY2020Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
78651000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
86534000
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
60000
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.95
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.12
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.95
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5846000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6559000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17483000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20907000
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5726544
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4550669
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5728147
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
7819000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-32941000
us-gaap Net Income Loss
NetIncomeLoss
-53477000
us-gaap Net Income Loss
NetIncomeLoss
-95976000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62144118
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49820455
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57377581
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49246684
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62697173
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49820455
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57377581
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49246684
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3997614

Files In Submission

Name View Source Status
0001558370-20-013022-index-headers.html Edgar Link pending
0001558370-20-013022-index.html Edgar Link pending
0001558370-20-013022.txt Edgar Link pending
0001558370-20-013022-xbrl.zip Edgar Link pending
edit-20200930.xsd Edgar Link pending
edit-20200930x10q.htm Edgar Link pending
edit-20200930x10q_htm.xml Edgar Link completed
edit-20200930xex10d1.htm Edgar Link pending
edit-20200930xex31d1.htm Edgar Link pending
edit-20200930xex31d2.htm Edgar Link pending
edit-20200930xex32d1.htm Edgar Link pending
edit-20200930_cal.xml Edgar Link unprocessable
edit-20200930_def.xml Edgar Link unprocessable
edit-20200930_lab.xml Edgar Link unprocessable
edit-20200930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending